ROCK STUDY in CF: sustained anti-inflammatory effects of lumacaftor-ivacaftor in sputum and peripheral blood samples of adult patients with cystic fibrosis-an observational study.

Thumbnail
Name:
bmjresp-2022-001590.pdf
Size:
631.6Kb
Format:
PDF
Download
Authors
Morrissy, David V
McCarthy, Mairead
Eustace, Joseph A
Murphy, Desmond M
Plant, B J
Arooj, Parniya cc
McCarthy, Yvonne cc
Vagg, Tamara cc
Fleming, Claire cc
Daly, Mary cc
Issue Date
2023-05
Keywords
cystic fibrosis
inflammation

Metadata
Show full item record
Journal
BMJ open respiratory research
URI
http://hdl.handle.net/10147/638413
DOI
10.1136/bmjresp-2022-001590
PubMed ID
37130650
PubMed Central ID
PMC10163494
Abstract
Previous studies showed that the combination of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) corrector and potentiator, lumacaftor-ivacaftor (LUMA-IVA) provides meaningful clinical benefits in patients with cystic fibrosis who are homozygous for the Phe508del CFTR mutation. However, little is known about the effect of LUMA-IVA on Proinflammatory Cytokines (PICs).
Item Type
Article
Other
Language
en
EISSN
2052-4439
Collections